RxDoctor Payments Data

Sarah Doll

Family · Grandview, MONPI 1164969143

Payments from drug & device makers

$2,186in general payments, 2019–2025

Across 132 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$650
  • AstraZeneca$197
  • Novo Nordisk$136
  • Amgen$124
  • Merck$102
  • Biohaven Pharmaceutical Holding Company Ltd.$93
  • plus $884 from 23 others

What the payments were for

  • Food & beverage$2,11297%
  • Education$733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,186 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$17,623
Medicare patients
52
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$121,333
OzempicSemaglutide55$90,535
EliquisApixaban51$62,896
XareltoRivaroxaban31$37,637
Xultophy 100-3.6Insulin Degludec/Liraglutide17$28,505
EntrestoSacubitril/Valsartan14$27,530
LinzessLinaclotide24$25,500
MounjaroTirzepatide21$24,323
Spiriva RespimatTiotropium Bromide21$17,294
JanuviaSitagliptin Phosphate15$16,624
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$10,539
SymbicortBudesonide/Formoterol Fumarate24$8,036
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,076
ArexvyRsvpref3 Antigen/As01e/Pf16$4,034
AbrysvoRsv Vacc, Pref A And Pref B/Pf13$3,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$78$149,166115 claims
Novo NordiskOzempic, Xultophy 100-3.6$136$119,03972 claims
PfizerEliquis, Abrysvo$14$66,52564 claims
NovartisEntresto$17$27,53014 claims
AbbVieLinzess$650$25,50024 claims
Lilly USA, LLCMounjaro$93$24,32321 claims
MerckJanuvia$102$16,62415 claims
AstraZenecaSymbicort$197$8,03624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in Grandview

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →